{"id":391336,"date":"2015-09-08T00:00:00","date_gmt":"2015-09-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus0215-biopharma-how-will-u-s-physicians-and-payers-respond-to-additional-laba-lama-fdcs-in-the-increasingly-crowded\/"},"modified":"2026-04-27T23:45:00","modified_gmt":"2026-04-27T23:45:00","slug":"pforus0215-biopharma-how-will-u-s-physicians-and-payers-respond-to-additional-laba-lama-fdcs-in-the-increasingly-crowded","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus0215-biopharma-how-will-u-s-physicians-and-payers-respond-to-additional-laba-lama-fdcs-in-the-increasingly-crowded\/","title":{"rendered":"How Will U.S. Physicians and Payers Respond to Additional LABA\/LAMA FDCs in the Increasingly Crowded COPD Market? | Physician &#038; Payer Forum | US | 2015"},"content":{"rendered":"<p><em>A Survey of Pulmonologists and Managed Care Organization Pharmacy and Medical Directors <\/em><\/p>\n<p>The U.S. market for chronic obstructive pulmonary disease (COPD) therapies consists entirely of symptomatic treatments, namely bronchodilators and anti-inflammatory agents, which improve patients\u2019 quality of life (QOL) but do not alter the natural history of the disease. Surveyed physicians tend to favor well-established treatments, such as the long-acting muscarinic antagonist (LAMA) Spiriva (Boehringer Ingelheim\u2019s Spiriva) and the long-acting beta2 agonist (LABA)\/inhaled corticosteroid (ICS) fixed-dose combination (FDC) Advair (GlaxoSmithKline\u2019s salmeterol\/fluticasone propionate). In addition, alternative FDCs such as Anoro (GlaxoSmithKline\/Theravance\u2019s vilanterol\/umeclidinium) are beginning to gain market share, and generic versions of popular agents are expected in the coming years. Changes in prescribing habits to accommodate the new therapies are expected, and payers will likely update their formularies to accommodate the launch of multiple FDCs and generics. In this report, we gauge physicians\u2019 and payers\u2019 opinions of current and emerging therapies for COPD to anticipate potential changes in the prescribing patterns and reimbursement climate.<\/p>\n","protected":false},"template":"","class_list":["post-391336","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391336\/revisions"}],"predecessor-version":[{"id":576941,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391336\/revisions\/576941"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}